Shilpa Medicare Limited — Important, 16-07-2025: General Updates

Shilpa Medicare's Bengaluru Unit VI received a "Voluntary Action Indicated (VAI)" classification in its USFDA Establishment Inspection Report (EIR). This is a positive outcome, indicating no significant issues requiring mandatory action. The facility manufactures Oral Dissolving Films and Transdermal Systems. It holds approvals from major global agencies and supplies oral film products to the US market. The VAI status is crucial for ensuring continued compliance and market access, reinforcing operational stability and prospects in key international markets.